Read by QxMD icon Read

HCC Diagnosis

Chi-Jen Chen, Yao-Hsu Yang, Meng-Hung Lin, Chuan-Pin Lee, Yu-Tse Tsan, Ming-Nan Lai, Hsiao-Yu Yang, Wen-Chao Ho, Pau-Chung Chen
It was suspected that aristolochic acid-induced mutations may be associated with hepatitis B virus (HBV), playing an important role in liver carcinogenesis. The purpose of this study was to investigate the association between the use of Chinese herbs containing aristolochic acid and the risk of hepatocellular carcinoma (HCC) among HBV-infected patients. We conducted a retrospective, population-based, cohort study on patients older than 18 years who had a diagnosis of HBV infection between January 1, 1997 and December 31, 2010 and had visited traditional Chinese medicine clinics before one year before the diagnosis of HCC or the censor dates...
April 18, 2018: International Journal of Cancer. Journal International du Cancer
Hiroko Okinaga, Hideo Yasunaga, Kiyoshi Hasegawa, Kiyohide Fushimi, Norihiro Kokudo
Background: As the population is aging, the indication for hepatocellular carcinoma (HCC) resection in patients aged over 80 years will increase. Japan is facing the most aging society worldwide. We examined the safety of hepatectomy in octogenarians and nonagenarians using large-scale data from the Diagnosis Procedure Combination database, a national administrative database in Japan. Method: We conducted a survey to collect data for all inpatients from 2007 and 2012...
March 2018: Liver Cancer
Grzegorz Boryczka, Marek Hartleb, Małgorzata Janik
Introduction: Diagnosis of hepatocellular carcinoma (HCC) is considerably delayed, being frequently done in the non-curative stage of disease. The reason for delayed diagnosis is indolent course in early stages and/or unspecific symptoms indistinguishable from underlying cirrhosis. Hitherto methods used for screening of HCC have important limitations. TRIMprob is a non-invasive method, which showed utility in detection of cancers located in prostate, breast, or urinary bladder. Aim: To determine the diagnostic accuracy of TRIMprob in detecting HCC in cirrhotic liver...
2018: Przegla̜d Gastroenterologiczny
Vincenza Calvaruso, Giuseppe Cabibbo, Irene Cacciola, Salvatore Petta, Salvatore Madonia, Alessandro Bellia, Fabio Tinè, Marco Distefano, Anna Licata, Lydia Giannitrapani, Tullio Prestileo, Giovanni Mazzola, Maria Antonietta Di Rosolini, Licia Larocca, Gaetano Bertino, Antonio Digiacomo, Francesco Benanti, Luigi Guarneri, Alfonso Averna, Carmelo Iacobello, Antonio Magro, Ignazio Scalisi, Fabio Cartabellotta, Francesca Savalli, Marco Barbara, Antonio Davì, Maurizio Russello, Gaetano Scifo, Giovanni Squadrito, Calogero Cammà, Giovanni Raimondo, Antonio Craxì, Vito Di Marco
BACKGROUND & AIMS: Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with in hepatitis C virus (HCV)-associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world. METHODS: We collected data from a large prospective study of 2249 consecutive patients (mean age, 65.4 years and 56...
April 12, 2018: Gastroenterology
Hong Xu, Yueming Chen, Xueyan Dong, Xianjun Wang
BACKGROUND: Increasing studies suggest that lncRNAs involving in carcinogenesis of human cancers, which might be used as diagnostic biomarkers for cancers Methods:Three hundred and one participants were recruited in the first part of the study including HCC group (n = 60), LC group (n = 85), CHB group (n = 96) and healthy subjects (n = 60). In the second part, we collected 55 HCC patients, 60 CHB patients and 60 healthy subjects as an independent cohort to validate the ability of the experiential lncRNAs for identifying HCC from CHB...
April 12, 2018: Cancer Epidemiology, Biomarkers & Prevention
Won-Tak Choi, Sanjay Kakar
The distinction of hepatocellular adenoma from well-differentiated hepatocellular carcinoma (HCC) can be difficult in some cases, especially on biopsy specimens. These borderline cases often occur in men or older patients and may have β-catenin activation or focal atypical morphologic features (such as small cell change, prominent pseudoacinar formation, cytologic atypia, focally thick plates, and/or focal reticulin loss) that are insufficient for an unequivocal diagnosis of HCC. The term "atypical hepatocellular neoplasm" has been advocated for these tumors, but a number of other terms, including "atypical adenoma," "hepatocellular neoplasm of uncertain malignant potential," and "well-differentiated hepatocellular neoplasm with atypical or borderline features" have also been proposed...
April 11, 2018: Advances in Anatomic Pathology
Rashi Garg, Radhika Srinivasan, Pranab Dey, Priya Singh, Nalini Gupta, Arvind Rajwanshi
Objective: To distinguish fibrolamellar hepatocellular carcinoma (FL-HCC) variant from the conventional hepatocellular carcinoma (HCC) by cytology, immunocytochemistry, and morphometry. Study Design: Retrospective detailed cytomorphological, immunocytochemical, and morphometric analysis was performed in 6 cases of FL-HCC reported on fine needle aspiration. Cell block immunocytochemistry (CB-ICC) for CK7 and CD68 was performed in four cases. Morphometry was carried out with Cell A software...
April 2018: Journal of Cytology
Ann Robinson, Hesam Tavakoli, Ramsey Cheung, Benny Liu, Taft Bhuket, Robert J Wong
GOALS: To evaluate rates and predictors of retention into hepatocellular carcinoma (HCC) surveillance beyond initial screening among underserved cirrhosis patients. BACKGROUND: Although initial HCC screening among cirrhosis patients remains low, few studies have evaluated retention to HCC surveillance beyond initial screening. METHODS: We retrospectively evaluated all consecutive adults with cirrhosis from 2014 to 2017 at a single underserved safety net hospital system to determine rates of HCC surveillance at 6 months and at 1 year beyond initial screening...
April 6, 2018: Journal of Clinical Gastroenterology
Abderrahim Oussalah, Susann Rischer, Mouni Bensenane, Guillaume Conroy, Pierre Filhine-Tresarrieu, Renée Debard, Denise Forest-Tramoy, Thomas Josse, Dana Reinicke, Matthieu Garcia, Amandine Luc, Cédric Baumann, Ahmet Ayav, Valérie Laurent, Marcus Hollenbach, Cristina Ripoll, Rosa-Maria Guéant-Rodriguez, Fares Namour, Alexander Zipprich, Michael Fleischhacker, Jean-Pierre Bronowicki, Jean-Louis Guéant
BACKGROUND: Patients with cirrhosis are at high risk of hepatocellular carcinoma (HCC). The SEPT9 gene is a key regulator of cell division and tumor suppressor whose hypermethylation is associated with liver carcinogenesis. The primary aim of this study was to evaluate the diagnostic accuracy of a PCR-based assay for the analysis of SEPT9 promoter methylation in circulating cell-free DNA (mSEPT9) for diagnosing HCC among cirrhotic patients. METHODS: We report two phase II biomarker studies that included cirrhotic patients with or without HCC from France (initial study) and Germany (replication study)...
March 28, 2018: EBioMedicine
Ting-Juan Zhang, Zhen Qian, Xiang-Mei Wen, Jing-Dong Zhou, Xi-Xi Li, Zi-Jun Xu, Ji-Chun Ma, Zhi-Hui Zhang, Jiang Lin, Jun Qian
BACKGROUND: The liver-enriched microRNA-122 (miR-122) plays a crucial role in pathogenesis of hepatocellular carcinoma (HCC) with prognostic value. Recently, miR-122 was also found to be related to many other cancers besides HCC. However, less study determined miR-122 expression and its clinical significance in acute myeloid leukemia (AML). METHODS: Real-time quantitative PCR was performed to detect the level of bone marrow (BM) miR-122 in de novo AML patients. The clinical significance of miR-122 expression in AML was further investigated...
April 3, 2018: Pathology, Research and Practice
Xiao-Lu Ma, Mi Jiang, Ying Zhao, Bei-Li Wang, Min-Na Shen, Yan Zhou, Chun-Yan Zhang, Yun-Fan Sun, Jian-Wen Chen, Bo Hu, Zi-Jun Gong, Xin Zhang, Ya Cao, Bai-Shen Pan, Jian Zhou, Jia Fan, Xin-Rong Yang, Wei Guo
PURPOSE: Annexin A3 (ANXA3) could induce progression of hepatocellular carcinoma (HCC) via promoting stem cell traits of CD133-positive cells. Moreover, serum ANXA3 showed preliminary diagnostic potential, however further validation was required. Meanwhile, the prognostic value of ANXA3 remained elusive. The present study aimed to validate diagnostic performance and further systematically investigate the prognostic value of serum ANXA3. METHODS: Serum ANXA3 of 368 HCC patients was determined by enzyme-linked immunosorbent assay (ELISA); 295 of these patients underwent resection and 73 underwent transcatheter arterial chemoembolization (TACE)...
April 6, 2018: Annals of Surgical Oncology
Nathan G Kim, Pauline P Nguyen, Hansen Dang, Radhika Kumari, Gabriel Garcia, Carlos O Esquivel, Mindie H Nguyen
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the few cancers whose incidence continues to increase. The goal of the current study was to investigate the presentation and survival trends of patients with HCC presenting to a university hospital between 1998 and 2015. METHODS: Study data were ascertained by individual chart review with survival data also supplemented by National Death Index query up to December 31, 2015. Patients were divided into three 6-year groups by diagnosis date (1998-2003, 2004-2009, and 2010-2015)...
April 6, 2018: Cancer
Ahmed M Tahon, Magdy Z El-Ghanam, Samy Zaky, Tarek Mostafa Emran, Ali M Bersy, Fathiya El-Raey, Elsayed A Z, Amr M El Kharsawy, Dina Johar
BACKGROUND: Egypt has high incidence of hepatocellular carcinoma (HCC). This is due to wide spread of hepatitis C virus (HCV) infection which is responsible for most of the cases of liver cirrhosis. The major diagnostic techniques for HCC include serum markers and various imaging modalities. Glypican 3 (GPC3) protein is highly expressed in HCC, but not in normal liver tissue. The significance of GPC3 as a predictor or diagnostic tool for human tumors other than HCC is unclear. AIM: To quantitatively assess the role of GPC3 in diagnosis of HCC in comparison to α-fetoprotein (AFP), ultrasonography (US), and computerized tomography (CT)...
April 6, 2018: Journal of Gastrointestinal Cancer
Honggang Wang, Fuguo Jiang, Furong Hao, Ruixue Ju
The purpose of this study was to detect the expression of high-temperature requirement A2 (HtrA2) and its diagnostic value in the patients with hepatocellular carcinoma (HCC).The relative serum HtrA2 expression at mRNA and protein level was severally detected by quantitative real-time polymerase chain reaction and western blot analysis in 198 HCC patients and 48 healthy controls. And its association with clinicopathological features was analyzed by chi-square test. The diagnostic value of HtrA2 expression was estimated by establishing a receiver operating characteristic (ROC) curve...
April 2018: Medicine (Baltimore)
H Y Kim, J Y Nam, J-H Lee, H A Lee, Y Chang, H Y Lee, H Cho, D H Lee, Y Y Cho, E J Cho, S J Yu, J M Lee, Y J Kim, J-H Yoon
BACKGROUND: Data are insufficient regarding the survival benefit of surveillance for hepatocellular carcinoma (HCC). AIMS: To investigate the effectiveness of HCC surveillance in a hepatitis B-endemic population. METHODS: This retrospective cohort study included 1402 consecutive patients who were newly diagnosed with HCC between 2005 and 2012 at a single tertiary hospital in Korea. The primary endpoint was overall survival. Lead-time and length-time biases were adjusted (sojourn time = 140 days) and sensitivity analyses were performed...
April 2, 2018: Alimentary Pharmacology & Therapeutics
Kwang Min Kim, Jiyu Kim, Dong Hyun Sinn, Hye Seung Kim, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
OBJECTIVE: In order to claim a benefit of screen-based diagnosis for asymptomatic individuals, treatment of occult disease needs to offer survival advantages compared to the treatment of symptomatic disease, yet information on this issue is scarce with regard to hepatocellular carcinoma (HCC) screening. METHODS: A total of 3353 treatment-naïve, consecutive, newly diagnosed HCC patients [age: 57.9 ± 10.3, male: 2,689 (80.2%), hepatitis B virus: 2555 (76.2%)], diagnosed between 2010 and 2013 were analyzed...
April 3, 2018: Scandinavian Journal of Gastroenterology
Chia-Yang Hsu, Po-Hong Liu, Shu-Yein Ho, Yi-Hsiang Huang, Yun-Hsuan Lee, Rheun-Chuan Lee, Teddy S Nagaria, Ming-Chih Hou, Teh-Ia Huo
BACKGROUND & AIM: Patients with hepatocellular carcinoma (HCC) and metastasis are classified as advanced or terminal stage by the Barcelona Clinic Liver Cancer (BCLC) system. This study investigates the prevalence, determinants, and prognostic effect of metastasis, and its ability to improve the BCLC system. METHODS: A total of 3,414 patients were enrolled. The Kaplan-Meier and Cox regression methods were used to determine survival predictors. Akaike information criterion (AIC) was used to compare the prognostic performance of staging systems...
April 2, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Saleh Daher, Muhammad Massarwa, Ariel A Benson, Tawfik Khoury
Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related mortality. The principal treatment is surgical resection or liver transplantation, depending on whether the patient is a suitable transplant candidate. However, in most patients with HCC the diagnosis is often late, thereby excluding the patients from definitive surgical resection. Medical treatment includes sorafenib, which is the most commonly used systemic therapy; although, it has been shown to only minimally impact patient survival by several months...
March 28, 2018: Journal of Clinical and Translational Hepatology
Xi Chen, Qi Zhang, Weijie Ma, Tian Lan, Zhenfei Hong, Yufeng Yuan
Aim: To evaluate the expression of miRNA-542-3p in hepatocellular carcinoma, establish its function, and evaluate whether it could serve as a biomarker for diagnosis and prognosis of HCC patients. Methods: qRT-PCR analysis was performed to determine the expression level of miRNA-542-3p in normal liver cells and HCC cell lines. Additionally, samples from TCGA consortium and from our patients were analyzed using biostatistical methods to ascertain whether miR-542-3p could be a good biomarker for HCC diagnosis and prognosis...
2018: Disease Markers
Bogdan Procopet, Petra Fischer, Oana Farcau, Horia Stefanescu
Currently there is a lack of accurate biomarkers for diagnosis and prognosis in advanced liver diseases. Either the occurrence of first decompensation, or diagnosis of acute on chronic liver failure, severe alcoholic hepatitis, or hepatocellular carcinoma (HCC), none of the available biomarkers are satisfactory. Metabolomics is the newest of omics, being much closer than the others to the actual phenotype and pathologic changes that characterizes a certain condition. It deals with a much wider spectrum of low molecular weight bio-compounds providing a powerful platform for discovering novel biomarkers and biochemical pathways to improve diagnostic, prognostication and therapy...
March 27, 2018: World Journal of Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"